ASH 2021 Conference Coverage on VuMedi

 

Myeloma
05:27

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Sustained Improvement in HRQoL in Transplant-Ineligible Patients With NDMM Treated With D-Rd vs. Rd: Update of the Phase 3 MAIA Trial

FEATURING Aurore Perrot
  • 83 views
  • February 26, 2022
10:50

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: CARTITUDE-1 Subgroup Analysis

FEATURING Andrzej Jakubowiak
  • 187 views
  • February 23, 2022
  • 2
13:38

ASH 2021 Conference Coverage on VuMedi

2022 Updates on CAR T-Cell Therapy for Myeloma

FEATURING Larry Anderson
  • 43 views
  • February 8, 2022
05:57

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Impact of EPd on HRQoL for Patients With R/R MM: Final Data From the Phase 2 ELOQUENT-3 Trial

FEATURING Katja Weisel
  • 295 views
  • January 26, 2022
05:25

ASH 2021 Conference Coverage on VuMedi

ASH 2021 on the Efficacy and Safety of Cilta-cel in Len-Refractory Patients With Progressive MM After 1-3 Prior Lines of Therapy: Updated Results From CARTITUDE-2

FEATURING Yael C. Cohen
  • 61 views
  • January 26, 2022
08:31

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updated Results From the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients With R/R MM

FEATURING Noopur S. Raje
  • 13 views
  • January 24, 2022
16:29

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Review of MRD in MM: Why, When, Where, and How?

FEATURING Noopur S. Raje
  • 179 views
  • January 24, 2022
  • 1
13:12

ASH 2021 Conference Coverage on VuMedi

ASH 2021: Addressing Current Questions and Controversies in the Management of Multiple Myeloma

FEATURING Morie Gertz
  • 388 views
  • January 18, 2022
  • 4
07:41

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Cilta-Cel for Triple-Class Exposed MM: Adjusted Comparison of CARTITUDE-1 Patient Outcomes vs. Real-World Clinical Practice From the LocoMMotion Study

FEATURING Maria-Victoria Mateos
  • 121 views
  • January 13, 2022
04:34

ASH 2021 Conference Coverage on VuMedi

ASH 2021 on the Safety, Tolerability, PK/PD, and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in R/R Hematologic Malignancies

FEATURING Nina Shah
  • 64 views
  • January 13, 2022
04:19

ASH 2021 Conference Coverage on VuMedi

ASH 2021: Risk of Infections With BCMA-Directed Immunotherapy in Multiple Myeloma

FEATURING Meera Mohan
  • 85 views
  • January 11, 2022
07:00

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Outcomes in HR-MM Treated With Daratumumab

FEATURING Frits van Rhee
  • 116 views
  • December 22, 2021
  • 1
13:23

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Treatment Options for AL Amyloidosis Patients Ineligible for Autologous Transplantation

FEATURING Efstathios Kastritis
  • 103 views
  • December 20, 2021
09:07

ASH 2021 Conference Coverage on VuMedi

ASH 2021: Genomic and Immune Signatures Predict Sustained MRD Negativity in NDMM Patients Treated with D-KRd

FEATURING Eileen Boyle
  • 166 views
  • December 16, 2021
  • 1
06:08

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Efficacy and Safety of Ruxolitinib and Steroids for R/R MM

FEATURING James Berenson
  • 123 views
  • December 16, 2021
11:03

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Lecture on Clinical Outcomes of R/R MM Patients Following Treatment With Bispecific Antibodies

FEATURING Tarek Mouhieddine
  • 73 views
  • December 16, 2021